RESEARCH TRIANGLE PARK, NC (September 28, 2020) – Dignify Therapeutics LLC, a drug and medical device development company focused on restoring bladder and bowel control for people with spinal injury, multiple sclerosis, diabetes, and the elderly, has been awarded five new National Institutes of Health (NIH) awards in 2019-2020. These grants provide over $2.5 million in additional funding for Dignify to support development of novel drugs and medical devices. Dignify has received 16 separate grants from the NIH totaling approximately $15 million over the past seven years.

“These new awards from the NIH will further Dignify’s mission of restoring voluntary control of bladder and bowel function in people suffering from urinary and bowel retention and incontinence” said company Vice President and Principal Investigator, Dr. Lesley Marson. “Our pipeline of diverse therapeutic programs continues to expand to reach additional patient populations”.

Dignify is developing novel drug and device therapies for bladder and bowel dysfunction to eliminate or reduce the need for life-long, multiple-daily catheterization of the bladder and difficult and time-consuming manual bowel programs. Worldwide bladder catheter sales total $3 billion/year, while health care expenditures associated with voiding dysfunction cost $7 billion/year in the US alone. Success of Dignify’s development programs will not only improve the quality of life for individuals with voiding dysfunction but will also reduce health care costs.

Individual grants include: R43NS115169, R43NS115215, R41NS117205 and R44NS115169 from the National Institute of Neurological Disorders and Stroke (NINDS), and R43DK125131 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

 

About Dignify Therapeutics LLC

Founded by a team of serial entrepreneurs who are internationally-recognized scientists and clinicians, Dignify Therapeutics’ mission is to provide safe, effective, practical and convenient, treatments for bladder and bowel voiding dysfunctions, primarily using a repositioning strategy of drug discovery that the team has successfully implemented multiple times over the last 20 years in the fields of urology and gastroenterology. The Company is funded through venture capital (RA Capital Mgmt and Eshelman Ventures), angel investors, the NIH, the North Carolina Biotechnology Center and the One NC Small Business Program. Dignify Therapeutics is located at the First Flight Venture Center in Research Triangle Park, North Carolina.

This content is solely the responsibility of Dignify Therapeutics and does not necessarily represent the official views of the NIH.

PRESS CONTACT

Dignify Therapeutics

Ed Burgard

P.O. Box 13169

2 Davis Drive

Research Triangle Park, NC 27709

Phone: 919-371-8138

Email: eburgard@dignifytherapeutics.com

Website: https://dignifytherapeutics.com